nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—BLK—Kawasaki disease	0.692	1	CbGaD
Nilotinib—CYP2C8—Acetylsalicylic acid—Kawasaki disease	0.0352	0.421	CbGbCtD
Nilotinib—CYP2C9—Acetylsalicylic acid—Kawasaki disease	0.0245	0.294	CbGbCtD
Nilotinib—ABCB1—Acetylsalicylic acid—Kawasaki disease	0.0238	0.285	CbGbCtD
Nilotinib—MAPK8—artery—Kawasaki disease	0.00365	0.0429	CbGeAlD
Nilotinib—MAPK8—endothelium—Kawasaki disease	0.00309	0.0363	CbGeAlD
Nilotinib—TIE1—endothelium—Kawasaki disease	0.00268	0.0315	CbGeAlD
Nilotinib—CDC42BPB—cardiac ventricle—Kawasaki disease	0.00227	0.0266	CbGeAlD
Nilotinib—TEK—artery—Kawasaki disease	0.0021	0.0247	CbGeAlD
Nilotinib—MAPK8—neck—Kawasaki disease	0.00204	0.0239	CbGeAlD
Nilotinib—MAPK8—myocardium—Kawasaki disease	0.00193	0.0227	CbGeAlD
Nilotinib—EPHB4—endothelium—Kawasaki disease	0.00186	0.0218	CbGeAlD
Nilotinib—TEK—endothelium—Kawasaki disease	0.00178	0.0209	CbGeAlD
Nilotinib—CA9—gall bladder—Kawasaki disease	0.00174	0.0205	CbGeAlD
Nilotinib—TIE1—myocardium—Kawasaki disease	0.00167	0.0196	CbGeAlD
Nilotinib—Haematemesis—Acetylsalicylic acid—Kawasaki disease	0.00155	0.0643	CcSEcCtD
Nilotinib—MAPK11—heart—Kawasaki disease	0.0015	0.0176	CbGeAlD
Nilotinib—CDC42BPB—heart—Kawasaki disease	0.00149	0.0175	CbGeAlD
Nilotinib—HCK—myocardium—Kawasaki disease	0.00146	0.0172	CbGeAlD
Nilotinib—EPHA3—heart—Kawasaki disease	0.00141	0.0166	CbGeAlD
Nilotinib—PDGFRA—gall bladder—Kawasaki disease	0.0014	0.0164	CbGeAlD
Nilotinib—CA3—cardiac ventricle—Kawasaki disease	0.00139	0.0164	CbGeAlD
Nilotinib—Hepatotoxicity—Acetylsalicylic acid—Kawasaki disease	0.00139	0.0579	CcSEcCtD
Nilotinib—MAPK8—heart—Kawasaki disease	0.00135	0.0158	CbGeAlD
Nilotinib—EPHA4—myocardium—Kawasaki disease	0.00133	0.0156	CbGeAlD
Nilotinib—MAPK8—skin of body—Kawasaki disease	0.00132	0.0155	CbGeAlD
Nilotinib—CA3—myocardium—Kawasaki disease	0.00131	0.0154	CbGeAlD
Nilotinib—MAPK14—neck—Kawasaki disease	0.00129	0.0152	CbGeAlD
Nilotinib—KIT—endothelium—Kawasaki disease	0.00129	0.0151	CbGeAlD
Nilotinib—CA14—cardiac ventricle—Kawasaki disease	0.00127	0.0149	CbGeAlD
Nilotinib—EPHB4—cardiac ventricle—Kawasaki disease	0.00123	0.0145	CbGeAlD
Nilotinib—Contusion—Acetylsalicylic acid—Kawasaki disease	0.00123	0.0512	CcSEcCtD
Nilotinib—MAP4K1—heart—Kawasaki disease	0.00122	0.0144	CbGeAlD
Nilotinib—Chest discomfort—Acetylsalicylic acid—Kawasaki disease	0.00122	0.0505	CcSEcCtD
Nilotinib—TEK—cardiac ventricle—Kawasaki disease	0.00118	0.0139	CbGeAlD
Nilotinib—TIE1—heart—Kawasaki disease	0.00117	0.0137	CbGeAlD
Nilotinib—EPHB4—myocardium—Kawasaki disease	0.00116	0.0136	CbGeAlD
Nilotinib—Gout—Acetylsalicylic acid—Kawasaki disease	0.00115	0.0478	CcSEcCtD
Nilotinib—Hearing impaired—Acetylsalicylic acid—Kawasaki disease	0.00113	0.0469	CcSEcCtD
Nilotinib—BRAF—heart—Kawasaki disease	0.00112	0.0131	CbGeAlD
Nilotinib—KIT—gall bladder—Kawasaki disease	0.00112	0.0131	CbGeAlD
Nilotinib—TEK—myocardium—Kawasaki disease	0.00111	0.0131	CbGeAlD
Nilotinib—EPHB3—heart—Kawasaki disease	0.00111	0.013	CbGeAlD
Nilotinib—PDGFRB—gall bladder—Kawasaki disease	0.00109	0.0128	CbGeAlD
Nilotinib—Melaena—Acetylsalicylic acid—Kawasaki disease	0.00105	0.0436	CcSEcCtD
Nilotinib—HCK—heart—Kawasaki disease	0.00102	0.012	CbGeAlD
Nilotinib—ABL2—heart—Kawasaki disease	0.00101	0.0119	CbGeAlD
Nilotinib—EPHA4—heart—Kawasaki disease	0.000927	0.0109	CbGeAlD
Nilotinib—CA3—heart—Kawasaki disease	0.000915	0.0108	CbGeAlD
Nilotinib—MAP2K5—myocardium—Kawasaki disease	0.000908	0.0107	CbGeAlD
Nilotinib—Diabetes mellitus—Acetylsalicylic acid—Kawasaki disease	0.000897	0.0373	CcSEcCtD
Nilotinib—Deafness—Acetylsalicylic acid—Kawasaki disease	0.000872	0.0363	CcSEcCtD
Nilotinib—MAPK14—heart—Kawasaki disease	0.000854	0.01	CbGeAlD
Nilotinib—FGR—heart—Kawasaki disease	0.000851	0.01	CbGeAlD
Nilotinib—LCK—heart—Kawasaki disease	0.000851	0.01	CbGeAlD
Nilotinib—KIT—neck—Kawasaki disease	0.000849	0.00999	CbGeAlD
Nilotinib—MAPK14—skin of body—Kawasaki disease	0.000837	0.00984	CbGeAlD
Nilotinib—PDGFRB—cardiac ventricle—Kawasaki disease	0.000835	0.00982	CbGeAlD
Nilotinib—CA14—heart—Kawasaki disease	0.000831	0.00977	CbGeAlD
Nilotinib—PDGFRB—neck—Kawasaki disease	0.00083	0.00976	CbGeAlD
Nilotinib—EPHB4—heart—Kawasaki disease	0.00081	0.00952	CbGeAlD
Nilotinib—KIT—myocardium—Kawasaki disease	0.000804	0.00946	CbGeAlD
Nilotinib—Hypoglycaemia—Acetylsalicylic acid—Kawasaki disease	0.0008	0.0332	CcSEcCtD
Nilotinib—EPHA2—heart—Kawasaki disease	0.000794	0.00934	CbGeAlD
Nilotinib—PDGFRB—myocardium—Kawasaki disease	0.000785	0.00924	CbGeAlD
Nilotinib—Gastrointestinal haemorrhage—Acetylsalicylic acid—Kawasaki disease	0.000781	0.0324	CcSEcCtD
Nilotinib—TEK—heart—Kawasaki disease	0.000775	0.00911	CbGeAlD
Nilotinib—ABL1—cardiac ventricle—Kawasaki disease	0.000744	0.00875	CbGeAlD
Nilotinib—EPHB6—heart—Kawasaki disease	0.000741	0.00871	CbGeAlD
Nilotinib—EPHB6—skin of body—Kawasaki disease	0.000725	0.00853	CbGeAlD
Nilotinib—Hypokalaemia—Acetylsalicylic acid—Kawasaki disease	0.00071	0.0295	CcSEcCtD
Nilotinib—PDGFRA—heart—Kawasaki disease	0.000702	0.00826	CbGeAlD
Nilotinib—ABL1—myocardium—Kawasaki disease	0.0007	0.00823	CbGeAlD
Nilotinib—Influenza—Acetylsalicylic acid—Kawasaki disease	0.000675	0.028	CcSEcCtD
Nilotinib—CA2—gall bladder—Kawasaki disease	0.000662	0.00779	CbGeAlD
Nilotinib—MAP2K5—heart—Kawasaki disease	0.000633	0.00745	CbGeAlD
Nilotinib—CSF1R—heart—Kawasaki disease	0.000618	0.00727	CbGeAlD
Nilotinib—CA4—cardiac ventricle—Kawasaki disease	0.000611	0.00719	CbGeAlD
Nilotinib—CA4—neck—Kawasaki disease	0.000607	0.00714	CbGeAlD
Nilotinib—CSF1R—skin of body—Kawasaki disease	0.000605	0.00712	CbGeAlD
Nilotinib—CA4—myocardium—Kawasaki disease	0.000575	0.00676	CbGeAlD
Nilotinib—KIT—heart—Kawasaki disease	0.000561	0.0066	CbGeAlD
Nilotinib—KIT—skin of body—Kawasaki disease	0.00055	0.00646	CbGeAlD
Nilotinib—PDGFRB—heart—Kawasaki disease	0.000548	0.00645	CbGeAlD
Nilotinib—Haemoglobin—Acetylsalicylic acid—Kawasaki disease	0.000543	0.0225	CcSEcCtD
Nilotinib—Haemorrhage—Acetylsalicylic acid—Kawasaki disease	0.00054	0.0224	CcSEcCtD
Nilotinib—PDGFRB—skin of body—Kawasaki disease	0.000537	0.00631	CbGeAlD
Nilotinib—CA1—heart—Kawasaki disease	0.000513	0.00604	CbGeAlD
Nilotinib—CA2—cardiac ventricle—Kawasaki disease	0.000507	0.00596	CbGeAlD
Nilotinib—CA2—neck—Kawasaki disease	0.000504	0.00592	CbGeAlD
Nilotinib—Tinnitus—Acetylsalicylic acid—Kawasaki disease	0.000503	0.0209	CcSEcCtD
Nilotinib—Flushing—Acetylsalicylic acid—Kawasaki disease	0.000501	0.0208	CcSEcCtD
Nilotinib—ABL1—heart—Kawasaki disease	0.000489	0.00575	CbGeAlD
Nilotinib—ABL1—skin of body—Kawasaki disease	0.000479	0.00563	CbGeAlD
Nilotinib—CA2—myocardium—Kawasaki disease	0.000477	0.00561	CbGeAlD
Nilotinib—Anaemia—Acetylsalicylic acid—Kawasaki disease	0.000434	0.018	CcSEcCtD
Nilotinib—Vertigo—Acetylsalicylic acid—Kawasaki disease	0.000422	0.0175	CcSEcCtD
Nilotinib—Syncope—Acetylsalicylic acid—Kawasaki disease	0.000422	0.0175	CcSEcCtD
Nilotinib—Leukopenia—Acetylsalicylic acid—Kawasaki disease	0.000421	0.0175	CcSEcCtD
Nilotinib—Loss of consciousness—Acetylsalicylic acid—Kawasaki disease	0.000413	0.0172	CcSEcCtD
Nilotinib—Hypertension—Acetylsalicylic acid—Kawasaki disease	0.000406	0.0169	CcSEcCtD
Nilotinib—CA4—heart—Kawasaki disease	0.000401	0.00472	CbGeAlD
Nilotinib—Arthralgia—Acetylsalicylic acid—Kawasaki disease	0.0004	0.0166	CcSEcCtD
Nilotinib—Chest pain—Acetylsalicylic acid—Kawasaki disease	0.0004	0.0166	CcSEcCtD
Nilotinib—Confusional state—Acetylsalicylic acid—Kawasaki disease	0.000387	0.0161	CcSEcCtD
Nilotinib—Shock—Acetylsalicylic acid—Kawasaki disease	0.000377	0.0157	CcSEcCtD
Nilotinib—Thrombocytopenia—Acetylsalicylic acid—Kawasaki disease	0.000376	0.0156	CcSEcCtD
Nilotinib—Tachycardia—Acetylsalicylic acid—Kawasaki disease	0.000374	0.0156	CcSEcCtD
Nilotinib—Hyperhidrosis—Acetylsalicylic acid—Kawasaki disease	0.000371	0.0154	CcSEcCtD
Nilotinib—Dyspnoea—Acetylsalicylic acid—Kawasaki disease	0.000342	0.0142	CcSEcCtD
Nilotinib—Dyspepsia—Acetylsalicylic acid—Kawasaki disease	0.000338	0.014	CcSEcCtD
Nilotinib—CA2—heart—Kawasaki disease	0.000333	0.00391	CbGeAlD
Nilotinib—CA2—skin of body—Kawasaki disease	0.000326	0.00383	CbGeAlD
Nilotinib—Feeling abnormal—Acetylsalicylic acid—Kawasaki disease	0.000316	0.0131	CcSEcCtD
Nilotinib—ABCG2—heart—Kawasaki disease	0.000308	0.00362	CbGeAlD
Nilotinib—Urticaria—Acetylsalicylic acid—Kawasaki disease	0.000305	0.0127	CcSEcCtD
Nilotinib—CYP2B6—heart—Kawasaki disease	0.000284	0.00334	CbGeAlD
Nilotinib—Hypersensitivity—Acetylsalicylic acid—Kawasaki disease	0.000283	0.0117	CcSEcCtD
Nilotinib—CYP2C9—heart—Kawasaki disease	0.000282	0.00331	CbGeAlD
Nilotinib—CYP2B6—skin of body—Kawasaki disease	0.000278	0.00327	CbGeAlD
Nilotinib—Pruritus—Acetylsalicylic acid—Kawasaki disease	0.000271	0.0113	CcSEcCtD
Nilotinib—Diarrhoea—Acetylsalicylic acid—Kawasaki disease	0.000262	0.0109	CcSEcCtD
Nilotinib—Dizziness—Acetylsalicylic acid—Kawasaki disease	0.000254	0.0105	CcSEcCtD
Nilotinib—Vomiting—Acetylsalicylic acid—Kawasaki disease	0.000244	0.0101	CcSEcCtD
Nilotinib—Rash—Acetylsalicylic acid—Kawasaki disease	0.000242	0.01	CcSEcCtD
Nilotinib—Dermatitis—Acetylsalicylic acid—Kawasaki disease	0.000242	0.01	CcSEcCtD
Nilotinib—Nausea—Acetylsalicylic acid—Kawasaki disease	0.000228	0.00947	CcSEcCtD
Nilotinib—ABCB1—heart—Kawasaki disease	0.000152	0.00179	CbGeAlD
Nilotinib—MAPK11—Innate Immune System—FCGR2A—Kawasaki disease	7.97e-05	0.000688	CbGpPWpGaD
Nilotinib—MAPK11—Signaling by VEGF—VEGFA—Kawasaki disease	7.95e-05	0.000686	CbGpPWpGaD
Nilotinib—EPHA8—Axon guidance—MMP9—Kawasaki disease	7.91e-05	0.000683	CbGpPWpGaD
Nilotinib—LYN—EPH-Ephrin signaling—MMP9—Kawasaki disease	7.83e-05	0.000676	CbGpPWpGaD
Nilotinib—EPHB4—Axon guidance—MMP9—Kawasaki disease	7.82e-05	0.000676	CbGpPWpGaD
Nilotinib—EPHA4—Axon guidance—MMP9—Kawasaki disease	7.82e-05	0.000676	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IL10—Kawasaki disease	7.81e-05	0.000675	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—CD40—Kawasaki disease	7.74e-05	0.000669	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ITPKC—Kawasaki disease	7.62e-05	0.000658	CbGpPWpGaD
Nilotinib—EPHB2—Axon guidance—MMP9—Kawasaki disease	7.58e-05	0.000655	CbGpPWpGaD
Nilotinib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	7.41e-05	0.00064	CbGpPWpGaD
Nilotinib—HCK—Focal Adhesion—VEGFA—Kawasaki disease	7.37e-05	0.000636	CbGpPWpGaD
Nilotinib—EPHA3—Axon guidance—VEGFA—Kawasaki disease	7.37e-05	0.000636	CbGpPWpGaD
Nilotinib—ABL2—Axon guidance—VEGFA—Kawasaki disease	7.37e-05	0.000636	CbGpPWpGaD
Nilotinib—EPHB6—Axon guidance—MMP9—Kawasaki disease	7.36e-05	0.000635	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—FCGR2A—Kawasaki disease	7.19e-05	0.000621	CbGpPWpGaD
Nilotinib—EPHA8—Axon guidance—VEGFA—Kawasaki disease	7.11e-05	0.000614	CbGpPWpGaD
Nilotinib—LYN—EPH-Ephrin signaling—VEGFA—Kawasaki disease	7.03e-05	0.000607	CbGpPWpGaD
Nilotinib—EPHA4—Axon guidance—VEGFA—Kawasaki disease	7.03e-05	0.000607	CbGpPWpGaD
Nilotinib—EPHB4—Axon guidance—VEGFA—Kawasaki disease	7.03e-05	0.000607	CbGpPWpGaD
Nilotinib—LCK—CXCR4-mediated signaling events—MMP9—Kawasaki disease	7.02e-05	0.000606	CbGpPWpGaD
Nilotinib—EPHA6—Axon guidance—MMP9—Kawasaki disease	6.92e-05	0.000597	CbGpPWpGaD
Nilotinib—EPHB2—Axon guidance—VEGFA—Kawasaki disease	6.8e-05	0.000588	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—FCGR2A—Kawasaki disease	6.8e-05	0.000588	CbGpPWpGaD
Nilotinib—KIT—Signaling by SCF-KIT—MMP9—Kawasaki disease	6.78e-05	0.000586	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—BLK—Kawasaki disease	6.69e-05	0.000578	CbGpPWpGaD
Nilotinib—MAPK8—Focal Adhesion—VEGFA—Kawasaki disease	6.68e-05	0.000577	CbGpPWpGaD
Nilotinib—BLK—Focal Adhesion—VEGFA—Kawasaki disease	6.68e-05	0.000577	CbGpPWpGaD
Nilotinib—FGR—Focal Adhesion—VEGFA—Kawasaki disease	6.65e-05	0.000575	CbGpPWpGaD
Nilotinib—MAPK8—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	6.65e-05	0.000574	CbGpPWpGaD
Nilotinib—EPHB6—Axon guidance—VEGFA—Kawasaki disease	6.61e-05	0.000571	CbGpPWpGaD
Nilotinib—EPHB3—Developmental Biology—MMP9—Kawasaki disease	6.57e-05	0.000567	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ITPKC—Kawasaki disease	6.47e-05	0.000558	CbGpPWpGaD
Nilotinib—HCK—Immune System—FCGR2A—Kawasaki disease	6.43e-05	0.000555	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by SCF-KIT—MMP9—Kawasaki disease	6.42e-05	0.000554	CbGpPWpGaD
Nilotinib—EPHA2—Axon guidance—MMP9—Kawasaki disease	6.38e-05	0.000551	CbGpPWpGaD
Nilotinib—MAP2K5—Focal Adhesion—VEGFA—Kawasaki disease	6.35e-05	0.000548	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—BLK—Kawasaki disease	6.34e-05	0.000547	CbGpPWpGaD
Nilotinib—BRAF—Integrated Breast Cancer Pathway—VEGFA—Kawasaki disease	6.33e-05	0.000547	CbGpPWpGaD
Nilotinib—HCK—Immune System—BLK—Kawasaki disease	6.24e-05	0.000539	CbGpPWpGaD
Nilotinib—EPHA6—Axon guidance—VEGFA—Kawasaki disease	6.21e-05	0.000536	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—FCGR2A—Kawasaki disease	6.13e-05	0.000529	CbGpPWpGaD
Nilotinib—LCK—HIV Infection—CCR5—Kawasaki disease	6.03e-05	0.000521	CbGpPWpGaD
Nilotinib—MAPK14—VEGFA-VEGFR2 Pathway—VEGFA—Kawasaki disease	6.01e-05	0.000519	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—FCGR2A—Kawasaki disease	6e-05	0.000518	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—FCGR2A—Kawasaki disease	5.97e-05	0.000516	CbGpPWpGaD
Nilotinib—EPHB3—Developmental Biology—VEGFA—Kawasaki disease	5.9e-05	0.000509	CbGpPWpGaD
Nilotinib—ABL2—Developmental Biology—MMP9—Kawasaki disease	5.85e-05	0.000506	CbGpPWpGaD
Nilotinib—EPHA3—Developmental Biology—MMP9—Kawasaki disease	5.85e-05	0.000506	CbGpPWpGaD
Nilotinib—LCK—Host Interactions of HIV factors—CD4—Kawasaki disease	5.83e-05	0.000504	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—FCGR2A—Kawasaki disease	5.83e-05	0.000503	CbGpPWpGaD
Nilotinib—BLK—Immune System—FCGR2A—Kawasaki disease	5.83e-05	0.000503	CbGpPWpGaD
Nilotinib—FGR—Immune System—FCGR2A—Kawasaki disease	5.81e-05	0.000502	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by SCF-KIT—MMP9—Kawasaki disease	5.78e-05	0.000499	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—CRP—Kawasaki disease	5.74e-05	0.000495	CbGpPWpGaD
Nilotinib—EPHA2—Axon guidance—VEGFA—Kawasaki disease	5.73e-05	0.000495	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—BLK—Kawasaki disease	5.71e-05	0.000493	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—FCGR2A—Kawasaki disease	5.69e-05	0.000491	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by VEGF—VEGFA—Kawasaki disease	5.67e-05	0.00049	CbGpPWpGaD
Nilotinib—LYN—Signaling by SCF-KIT—MMP9—Kawasaki disease	5.66e-05	0.000489	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—BLK—Kawasaki disease	5.65e-05	0.000488	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—MMP9—Kawasaki disease	5.65e-05	0.000488	CbGpPWpGaD
Nilotinib—FGR—Immune System—BLK—Kawasaki disease	5.63e-05	0.000487	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—BLK—Kawasaki disease	5.59e-05	0.000483	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—MMP9—Kawasaki disease	5.58e-05	0.000482	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—MMP9—Kawasaki disease	5.58e-05	0.000482	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD40—Kawasaki disease	5.56e-05	0.000481	CbGpPWpGaD
Nilotinib—EPHB2—Developmental Biology—MMP9—Kawasaki disease	5.41e-05	0.000467	CbGpPWpGaD
Nilotinib—BRAF—Focal Adhesion—VEGFA—Kawasaki disease	5.27e-05	0.000455	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD40—Kawasaki disease	5.27e-05	0.000455	CbGpPWpGaD
Nilotinib—ABL2—Developmental Biology—VEGFA—Kawasaki disease	5.26e-05	0.000454	CbGpPWpGaD
Nilotinib—EPHA3—Developmental Biology—VEGFA—Kawasaki disease	5.26e-05	0.000454	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—MMP9—Kawasaki disease	5.25e-05	0.000453	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—CRP—Kawasaki disease	5.2e-05	0.000449	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD40—Kawasaki disease	5.18e-05	0.000448	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—CRP—Kawasaki disease	5.18e-05	0.000447	CbGpPWpGaD
Nilotinib—MAPK8—Cellular responses to stress—VEGFA—Kawasaki disease	5.13e-05	0.000443	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—VEGFA—Kawasaki disease	5.07e-05	0.000438	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—VEGFA—Kawasaki disease	5.01e-05	0.000433	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—VEGFA—Kawasaki disease	5.01e-05	0.000433	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—MMP9—Kawasaki disease	4.94e-05	0.000426	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—FCGR2A—Kawasaki disease	4.92e-05	0.000425	CbGpPWpGaD
Nilotinib—EPHB2—Developmental Biology—VEGFA—Kawasaki disease	4.86e-05	0.000419	CbGpPWpGaD
Nilotinib—CA9—Cellular responses to stress—VEGFA—Kawasaki disease	4.84e-05	0.000418	CbGpPWpGaD
Nilotinib—ABL1—Integrated Breast Cancer Pathway—VEGFA—Kawasaki disease	4.79e-05	0.000414	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD40—Kawasaki disease	4.74e-05	0.00041	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ITPKC—Kawasaki disease	4.74e-05	0.000409	CbGpPWpGaD
Nilotinib—TEK—Hemostasis—VEGFA—Kawasaki disease	4.72e-05	0.000407	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—VEGFA—Kawasaki disease	4.71e-05	0.000407	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD40—Kawasaki disease	4.7e-05	0.000406	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD40—Kawasaki disease	4.7e-05	0.000406	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD40—Kawasaki disease	4.68e-05	0.000404	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD40—Kawasaki disease	4.65e-05	0.000401	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—FCGR2A—Kawasaki disease	4.64e-05	0.000401	CbGpPWpGaD
Nilotinib—LCK—Signaling by SCF-KIT—MMP9—Kawasaki disease	4.64e-05	0.000401	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—BLK—Kawasaki disease	4.58e-05	0.000396	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—MMP9—Kawasaki disease	4.55e-05	0.000393	CbGpPWpGaD
Nilotinib—PDGFRA—Focal Adhesion—VEGFA—Kawasaki disease	4.54e-05	0.000392	CbGpPWpGaD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	4.52e-05	0.00039	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—BLK—Kawasaki disease	4.5e-05	0.000389	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—VEGFA—Kawasaki disease	4.43e-05	0.000383	CbGpPWpGaD
Nilotinib—KIT—Immune System—FCGR2A—Kawasaki disease	4.19e-05	0.000362	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—CRP—Kawasaki disease	4.14e-05	0.000358	CbGpPWpGaD
Nilotinib—PDGFRB—Focal Adhesion—VEGFA—Kawasaki disease	4.09e-05	0.000353	CbGpPWpGaD
Nilotinib—MAPK11—Cellular responses to stress—VEGFA—Kawasaki disease	4.09e-05	0.000353	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—VEGFA—Kawasaki disease	4.09e-05	0.000353	CbGpPWpGaD
Nilotinib—KIT—Immune System—BLK—Kawasaki disease	4.06e-05	0.000351	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ITPKC—Kawasaki disease	4.01e-05	0.000347	CbGpPWpGaD
Nilotinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	4.01e-05	0.000346	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	3.97e-05	0.000343	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—FCGR2A—Kawasaki disease	3.96e-05	0.000342	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—CD4—Kawasaki disease	3.87e-05	0.000335	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—BLK—Kawasaki disease	3.84e-05	0.000332	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD40—Kawasaki disease	3.81e-05	0.000329	CbGpPWpGaD
Nilotinib—LCK—HIV Infection—CD4—Kawasaki disease	3.79e-05	0.000327	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	3.78e-05	0.000326	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD40—Kawasaki disease	3.74e-05	0.000323	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—CRP—Kawasaki disease	3.73e-05	0.000322	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—FCGR2A—Kawasaki disease	3.57e-05	0.000308	CbGpPWpGaD
Nilotinib—LYN—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	3.55e-05	0.000306	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CRP—Kawasaki disease	3.53e-05	0.000305	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—CD4—Kawasaki disease	3.51e-05	0.000303	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—CD4—Kawasaki disease	3.5e-05	0.000302	CbGpPWpGaD
Nilotinib—LYN—Immune System—FCGR2A—Kawasaki disease	3.5e-05	0.000302	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ITPKC—Kawasaki disease	3.5e-05	0.000302	CbGpPWpGaD
Nilotinib—ABL1—Immune System—FCGR2A—Kawasaki disease	3.48e-05	0.0003	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—VEGFA—Kawasaki disease	3.47e-05	0.0003	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BLK—Kawasaki disease	3.46e-05	0.000299	CbGpPWpGaD
Nilotinib—LYN—Immune System—BLK—Kawasaki disease	3.39e-05	0.000293	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BLK—Kawasaki disease	3.37e-05	0.000291	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD40—Kawasaki disease	3.37e-05	0.000291	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—CD4—Kawasaki disease	3.37e-05	0.000291	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	3.36e-05	0.000291	CbGpPWpGaD
Nilotinib—HCK—Immune System—CRP—Kawasaki disease	3.34e-05	0.000289	CbGpPWpGaD
Nilotinib—HCK—Disease—CCR5—Kawasaki disease	3.32e-05	0.000287	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—FCGR2A—Kawasaki disease	3.31e-05	0.000286	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ITPKC—Kawasaki disease	3.29e-05	0.000284	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ITPKC—Kawasaki disease	3.27e-05	0.000282	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—BLK—Kawasaki disease	3.21e-05	0.000278	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40—Kawasaki disease	3.19e-05	0.000276	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CRP—Kawasaki disease	3.18e-05	0.000275	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CRP—Kawasaki disease	3.12e-05	0.000269	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CRP—Kawasaki disease	3.1e-05	0.000268	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—VEGFA—Kawasaki disease	3.04e-05	0.000262	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CRP—Kawasaki disease	3.03e-05	0.000261	CbGpPWpGaD
Nilotinib—BLK—Immune System—CRP—Kawasaki disease	3.03e-05	0.000261	CbGpPWpGaD
Nilotinib—FGR—Immune System—CRP—Kawasaki disease	3.02e-05	0.000261	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CRP—Kawasaki disease	2.96e-05	0.000255	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—VEGFA—Kawasaki disease	2.92e-05	0.000252	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—MMP9—Kawasaki disease	2.91e-05	0.000251	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	2.91e-05	0.000251	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—MMP9—Kawasaki disease	2.9e-05	0.00025	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40—Kawasaki disease	2.88e-05	0.000249	CbGpPWpGaD
Nilotinib—LCK—Immune System—FCGR2A—Kawasaki disease	2.87e-05	0.000247	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40—Kawasaki disease	2.82e-05	0.000243	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40—Kawasaki disease	2.8e-05	0.000242	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—CD4—Kawasaki disease	2.8e-05	0.000242	CbGpPWpGaD
Nilotinib—LCK—Immune System—BLK—Kawasaki disease	2.78e-05	0.00024	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—MMP9—Kawasaki disease	2.76e-05	0.000238	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40—Kawasaki disease	2.67e-05	0.000231	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—VEGFA—Kawasaki disease	2.61e-05	0.000226	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—VEGFA—Kawasaki disease	2.6e-05	0.000225	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CRP—Kawasaki disease	2.56e-05	0.000221	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—CD4—Kawasaki disease	2.52e-05	0.000218	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—VEGFA—Kawasaki disease	2.48e-05	0.000214	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD4—Kawasaki disease	2.42e-05	0.000209	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CRP—Kawasaki disease	2.41e-05	0.000208	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CD4—Kawasaki disease	2.39e-05	0.000206	CbGpPWpGaD
Nilotinib—BRAF—Disease—CCR5—Kawasaki disease	2.37e-05	0.000205	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40—Kawasaki disease	2.31e-05	0.000199	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD4—Kawasaki disease	2.29e-05	0.000198	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD4—Kawasaki disease	2.26e-05	0.000195	CbGpPWpGaD
Nilotinib—KIT—Immune System—CRP—Kawasaki disease	2.17e-05	0.000188	CbGpPWpGaD
Nilotinib—KIT—Disease—CCR5—Kawasaki disease	2.16e-05	0.000187	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ITPKC—Kawasaki disease	2.15e-05	0.000186	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CD4—Kawasaki disease	2.15e-05	0.000186	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CD4—Kawasaki disease	2.11e-05	0.000182	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CCR5—Kawasaki disease	2.11e-05	0.000182	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CD4—Kawasaki disease	2.1e-05	0.000181	CbGpPWpGaD
Nilotinib—HCK—Disease—CD4—Kawasaki disease	2.08e-05	0.00018	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—MMP9—Kawasaki disease	2.08e-05	0.000179	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—MMP9—Kawasaki disease	2.07e-05	0.000178	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD4—Kawasaki disease	2.07e-05	0.000178	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CRP—Kawasaki disease	2.06e-05	0.000178	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD4—Kawasaki disease	2.04e-05	0.000177	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD4—Kawasaki disease	2.04e-05	0.000177	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CCR5—Kawasaki disease	2.04e-05	0.000177	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD4—Kawasaki disease	2.04e-05	0.000176	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD4—Kawasaki disease	2.02e-05	0.000175	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCR5—Kawasaki disease	2e-05	0.000173	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CD4—Kawasaki disease	2e-05	0.000172	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—MMP9—Kawasaki disease	1.97e-05	0.00017	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—VEGFA—Kawasaki disease	1.86e-05	0.000161	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—VEGFA—Kawasaki disease	1.86e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CRP—Kawasaki disease	1.85e-05	0.00016	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CCR5—Kawasaki disease	1.84e-05	0.000159	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—VEGFA—Kawasaki disease	1.83e-05	0.000158	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—VEGFA—Kawasaki disease	1.82e-05	0.000157	CbGpPWpGaD
Nilotinib—LYN—Immune System—CRP—Kawasaki disease	1.82e-05	0.000157	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CRP—Kawasaki disease	1.81e-05	0.000156	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—VEGFA—Kawasaki disease	1.77e-05	0.000153	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—VEGFA—Kawasaki disease	1.73e-05	0.00015	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—Kawasaki disease	1.73e-05	0.000149	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CRP—Kawasaki disease	1.72e-05	0.000149	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	1.71e-05	0.000148	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCR5—Kawasaki disease	1.68e-05	0.000145	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCR5—Kawasaki disease	1.66e-05	0.000143	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—Kawasaki disease	1.66e-05	0.000143	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—Kawasaki disease	1.63e-05	0.000141	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCR5—Kawasaki disease	1.51e-05	0.000131	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—VEGFA—Kawasaki disease	1.5e-05	0.000129	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—Kawasaki disease	1.49e-05	0.000129	CbGpPWpGaD
Nilotinib—LCK—Immune System—CRP—Kawasaki disease	1.49e-05	0.000129	CbGpPWpGaD
Nilotinib—LCK—Disease—CCR5—Kawasaki disease	1.48e-05	0.000128	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—Kawasaki disease	1.47e-05	0.000127	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCR5—Kawasaki disease	1.43e-05	0.000124	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—Kawasaki disease	1.39e-05	0.00012	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—Kawasaki disease	1.36e-05	0.000117	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR5—Kawasaki disease	1.29e-05	0.000111	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—Kawasaki disease	1.28e-05	0.000111	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR5—Kawasaki disease	1.26e-05	0.000109	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—Kawasaki disease	1.25e-05	0.000108	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—Kawasaki disease	1.23e-05	0.000106	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—Kawasaki disease	1.22e-05	0.000105	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—Kawasaki disease	1.2e-05	0.000103	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—Kawasaki disease	1.16e-05	0.0001	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—Kawasaki disease	1.16e-05	9.99e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MMP9—Kawasaki disease	1.15e-05	9.94e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MMP9—Kawasaki disease	1.09e-05	9.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—Kawasaki disease	1.04e-05	8.94e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—Kawasaki disease	1.03e-05	8.93e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—Kawasaki disease	1.01e-05	8.68e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—Kawasaki disease	9.83e-06	8.49e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—Kawasaki disease	9.28e-06	8.02e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MMP9—Kawasaki disease	9.17e-06	7.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MMP9—Kawasaki disease	9.09e-06	7.85e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—Kawasaki disease	8.27e-06	7.14e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—Kawasaki disease	8.24e-06	7.11e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—Kawasaki disease	8.16e-06	7.05e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—Kawasaki disease	7.83e-06	6.76e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—Kawasaki disease	7.43e-06	6.41e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—Kawasaki disease	7.05e-06	6.09e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—Kawasaki disease	7.03e-06	6.07e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—Kawasaki disease	6.91e-06	5.96e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—Kawasaki disease	6.55e-06	5.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—Kawasaki disease	6.33e-06	5.47e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—Kawasaki disease	6.2e-06	5.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—Kawasaki disease	5.88e-06	5.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—Kawasaki disease	5.66e-06	4.89e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—Kawasaki disease	5.08e-06	4.39e-05	CbGpPWpGaD
